Dongwha Pharm.Co.Ltd
Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, d… Read more
Dongwha Pharm.Co.Ltd (000020) - Total Assets
Latest total assets as of September 2025: ₩654.63 Billion KRW
Based on the latest financial reports, Dongwha Pharm.Co.Ltd (000020) holds total assets worth ₩654.63 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dongwha Pharm.Co.Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Dongwha Pharm.Co.Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Dongwha Pharm.Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Dongwha Pharm.Co.Ltd's total assets of ₩654.63 Billion consist of 38.4% current assets and 61.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 4.1% |
| Accounts Receivable | ₩78.54 Billion | 12.7% |
| Inventory | ₩89.33 Billion | 14.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩58.75 Billion | 9.5% |
| Goodwill | ₩24.93 Billion | 4.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Dongwha Pharm.Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dongwha Pharm.Co.Ltd's current assets represent 38.4% of total assets in 2024, a decrease from 39.0% in 2011.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2024, down from 10.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 1.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 14.4% of total assets.
Dongwha Pharm.Co.Ltd Competitors by Total Assets
Key competitors of Dongwha Pharm.Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
|
Yuyu Pharma Inc
KO:000227
|
Korea | ₩202.42 Billion |
Dongwha Pharm.Co.Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Dongwha Pharm.Co.Ltd generates 0.75x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Dongwha Pharm.Co.Ltd generates $ 0.90 in net profit.
Dongwha Pharm.Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.54 | 2.00 | 3.36 |
| Quick Ratio | 0.89 | 1.29 | 2.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩83.04 Billion | ₩ 108.82 Billion | ₩ 156.40 Billion |
Dongwha Pharm.Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Dongwha Pharm.Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.45 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 9.7% |
| Total Assets | ₩619.63 Billion |
| Market Capitalization | $75.32 Million USD |
Valuation Analysis
Below Book Valuation: The market values Dongwha Pharm.Co.Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Dongwha Pharm.Co.Ltd's assets grew by 9.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Dongwha Pharm.Co.Ltd (2011–2024)
The table below shows the annual total assets of Dongwha Pharm.Co.Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩619.63 Billion | +9.68% |
| 2023-12-31 | ₩564.97 Billion | +22.52% |
| 2022-12-31 | ₩461.14 Billion | +2.98% |
| 2021-12-31 | ₩447.80 Billion | +3.23% |
| 2020-12-31 | ₩433.81 Billion | +15.37% |
| 2019-12-31 | ₩376.03 Billion | +1.47% |
| 2018-12-31 | ₩370.60 Billion | +0.92% |
| 2017-12-31 | ₩367.23 Billion | +13.13% |
| 2016-12-31 | ₩324.60 Billion | +2.34% |
| 2015-12-31 | ₩317.19 Billion | +1.31% |
| 2014-12-31 | ₩313.07 Billion | -0.98% |
| 2013-12-31 | ₩316.17 Billion | -2.50% |
| 2012-12-31 | ₩324.28 Billion | -4.46% |
| 2011-12-31 | ₩339.43 Billion | -- |